SUNNYLIFE GLOBAL INC (SNYL)

[gamood]

Sunnylife Global, Inc. and Shandong Luyin Pharmaceutical Company Receive Formal Approvals From the People's Republic of China for Their Sino-U.S. Joint Venture to Produce Medicinal Products for Sale in China
Wednesday November 8, 10:50 am ET

LOS ANGELES, Nov. 8, 2006 (PRIMEZONE) -- Sunnylife Global, Inc. (Other OTC:SNYL.PK - News) announced today that it received formal approvals from the People's Republic of China for establishment of the Sino-U.S. Joint Venture with Shandong Luyin Pharmaceutical Company.

The approvals were issued in the forms of a Corporate Business License to operate the Sino-U.S. Joint Venture to produce medicinal products for sale in China and a Certificate of Approval for the Establishment of Enterprises with Foreign Investment in the People's Republic of China. The approvals were issued for 50 years to the year 2056.

Sunnylife Global, Inc. filed the legal documents requesting the approvals in August 2006 when it announced their joint venture with Shandong Luyin Pharmaceutical Co. ``We are so pleased to announce these early approvals of our filings,'' said Richard Lo, President of Sunnylife Global. ``Through this long-term cooperation with Shandong Luyin Pharmaceutical Company, we will offer the latest production and manufacturing technology, management systems and new product lines.''

Mr. Lo added, ``In addition, it will contribute to Sunnylife's Sino-US joint venture World Friendship Hospital Group by providing high quality medicine and a model that will build a platform for China-US medical industries to benefit from their joint venture investments.''

The newly formed Shandong Province Joint Venture Corporation is now expected to apply for listing in China. Under the terms of the 50-year agreements, Sunnylife Global, Inc. will own 58% of the total investment, currently valued at US$12.5 million (RMB 99.8 million).

Shandong Luyin Pharmaceutical Co. was founded in 2001 with a focus on the development and manufacture of Chinese herb medication and biotechnology. It has approximately 300 employees of which 80% are graduates from major medical institutions. Shandong Luyin received its GMP from the Chinese government in April 2003 and currently has 17 approved legal dosage medicinal products. It has developed 5 major categories of medicine -- for the cardio system, for the digestive system, for the suppression of tumors, for regulation of the metabolism, and the supplements.

About Sunnylife Global, Inc.

Sunnylife Global, Inc. has developed a Health Management System (HMS) in conjunction with the Chinese Government Authorities that will result in delivering superior quality health care management to its members. The Company is in multiple joint-venture agreements with the World Friendship Hospital Group to renovate and revitalize China's older hospital facilities in order to meet the current International standard. Sunnylife has developed the HMS to meet that standard and is planning to launch in the very near future. In addition, the Company has patented natural, environmentally safe and economically affordable products which it plans to introduce to Chinese consumers through seven different joint venture licensees in China. Sunnylife represents an organization staffed with professional experts in product research, quality acceptance testing, and market development for service to China and the global markets. For more information visit http://www.sunnylifeglobal.com.


Contact:

Financial Sciences of America
Investor Relations
Fran Daniels, President
[phone]
[e-mail]

Source: Sunnylife Global, Inc.